AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
16 août 2024 07h00 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
15 août 2024 12h17 HE
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
15 août 2024 09h00 HE
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
15 août 2024 04h00 HE
|
CV6 Therapeutics
– Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, including colon, gastric, breast, ovarian,...
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h30 HE
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
Press release Biocartis NV: Biocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer
13 août 2024 10h00 HE
|
Biocartis NV
PRESS RELEASE - 13/08/2024, 16:00 CEST Biocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer Mechelen, Belgium, 13 August 2024 –...
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
13 août 2024 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
13 août 2024 08h00 HE
|
Biomed Valley Discoveries, Inc.
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12 août 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update